• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of mutations on patients with drug-resistant TB treated with bedaquiline.

作者信息

Kaniga K, Lounis N, Zhuo S, Bakare N, Andries K

机构信息

Johnson & Johnson Global Public Health, Titusville, NJ, USA.

Janssen Pharmaceutica, Beerse, Belgium.

出版信息

Int J Tuberc Lung Dis. 2022 Jun 1;26(6):571-573. doi: 10.5588/ijtld.21.0670.

DOI:10.5588/ijtld.21.0670
PMID:35650698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9165736/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cbf/9165736/51c46b8630c3/i1815-7920-26-6-571-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cbf/9165736/51c46b8630c3/i1815-7920-26-6-571-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cbf/9165736/51c46b8630c3/i1815-7920-26-6-571-f01.jpg

相似文献

1
Impact of mutations on patients with drug-resistant TB treated with bedaquiline.突变对接受贝达喹啉治疗的耐多药结核病患者的影响。
Int J Tuberc Lung Dis. 2022 Jun 1;26(6):571-573. doi: 10.5588/ijtld.21.0670.
2
A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline.耐多药原发性肺结核伴巴德喹最低抑菌浓度值高 1 例
J Infect Chemother. 2022 Aug;28(8):1193-1197. doi: 10.1016/j.jiac.2022.04.028. Epub 2022 May 10.
3
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.在未记录有先前使用氯法齐明或贝达喹啉情况的耐多药结核病患者中，与耐药相关的Rv0678变体意外地具有高流行率。
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690. doi: 10.1093/jac/dkw502.
4
atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure.结核分枝杆菌 atpE 突变并不总是预示贝达喹啉治疗失败。
Emerg Infect Dis. 2022 May;28(5):1062-1064. doi: 10.3201/eid2805.212517.
5
The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.使用贝达喹啉治疗耐多药结核病和终末期肾病患者：一例报告。
Int J Infect Dis. 2018 Nov;76:88-90. doi: 10.1016/j.ijid.2018.09.009. Epub 2018 Sep 19.
6
Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.贝达喹啉：一种用于耐多药结核病的新型抗结核药物。
J Postgrad Med. 2014 Jul-Sep;60(3):300-2. doi: 10.4103/0022-3859.138772.
7
Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.在使用贝达喹啉治疗耐多药结核病后获得氯法齐明耐药性。
Int J Infect Dis. 2021 Jan;102:392-396. doi: 10.1016/j.ijid.2020.10.081. Epub 2020 Oct 29.
8
Bedaquiline: Introducing a new drug to the MDR TB armamentarium.贝达喹啉：向耐多药结核病治疗药物库中引入一种新药。
Indian J Tuberc. 2016 Jul;63(3):137-138. doi: 10.1016/j.ijtb.2016.08.003. Epub 2016 Sep 9.
9
Mutation in and genes associated with bedaquline resistance among drug-resistant tuberculosis patients: A pilot study from a high-burden setting in Northern India.和 基因突变与耐贝达喹啉结核病患者中的耐药性相关：来自印度北部高负担地区的一项初步研究。
Int J Mycobacteriol. 2020 Apr-Jun;9(2):212-215. doi: 10.4103/ijmy.ijmy_30_20.
10
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.贝达喹啉在儿童和青少年耐多药结核病中的超说明书使用。
Emerg Infect Dis. 2017 Oct;23(10):1711-3. doi: 10.3201/eid2310.170303. Epub 2017 Oct 17.

引用本文的文献

1
Structural and functional analysis of the MmpS5L5 efflux pump presages a pathway to increased bedaquiline resistance.MmpS5L5外排泵的结构和功能分析预示着增加对贝达喹啉耐药性的途径。
bioRxiv. 2025 Jun 24:2025.06.24.661325. doi: 10.1101/2025.06.24.661325.
2
Verapamil and its metabolite norverapamil inhibit the MmpS5L5 efflux pump to increase bedaquiline activity.维拉帕米及其代谢产物去甲维拉帕米可抑制MmpS5L5外排泵，从而增强贝达喹啉的活性。
Proc Natl Acad Sci U S A. 2025 Apr 22;122(16):e2426827122. doi: 10.1073/pnas.2426827122. Epub 2025 Apr 17.
3
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia.

本文引用的文献

1
Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.利奈唑胺治疗结核病过程中结核分枝杆菌的易感性降低及其与中国临床结局的相关性。
Clin Infect Dis. 2021 Nov 2;73(9):e3391-e3397. doi: 10.1093/cid/ciaa1002.
2
Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates.临床结核分枝杆菌分离株中贝达喹啉的敏感性降低和耐药性。
J Infect. 2020 May;80(5):527-535. doi: 10.1016/j.jinf.2020.01.007. Epub 2020 Jan 23.
3
Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study.
亚美尼亚耐多药结核病患者对贝达喹啉的表型和基因型耐药性——经验总结
Antimicrob Agents Chemother. 2025 May 7;69(5):e0183924. doi: 10.1128/aac.01839-24. Epub 2025 Apr 9.
4
High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia.俄罗斯：耐贝达喹啉结核分枝杆菌分离株中atpE基因突变的高流行率
Emerg Infect Dis. 2025 Mar;31(3):525-536. doi: 10.3201/eid3103.241488.
5
Mice infected with . with mutations still benefit from bedaquiline treatment.感染了……且有……突变的小鼠仍能从贝达喹啉治疗中获益。 （原文中“with...”部分表述不完整）
IJTLD Open. 2024 Nov 1;1(11):525-527. doi: 10.5588/ijtldopen.23.0527. eCollection 2024 Nov.
6
A dose-response model for statistical analysis of chemical genetic interactions in CRISPRi screens.用于 CRISPRi 筛选中化学遗传相互作用统计分析的剂量反应模型。
PLoS Comput Biol. 2024 May 20;20(5):e1011408. doi: 10.1371/journal.pcbi.1011408. eCollection 2024 May.
7
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.结核分枝杆菌复合体临床分离株中新药和再利用药物表型耐药相关的基因组突变及其相关性研究。
J Antimicrob Chemother. 2023 Nov 6;78(11):2637-2644. doi: 10.1093/jac/dkad252.
8
The evolving biology of drug resistance.耐药性的不断演变的生物学。
Front Cell Infect Microbiol. 2022 Oct 5;12:1027394. doi: 10.3389/fcimb.2022.1027394. eCollection 2022.
贝达喹啉表型药敏试验方法及断点的验证：一项多实验室、多国研究。
J Clin Microbiol. 2020 Mar 25;58(4). doi: 10.1128/JCM.01677-19.
4
Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.巴基斯坦结核病治疗后获得贝达喹啉和氯法齐明的交叉耐药性。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00915-19. Print 2019 Sep.
5
Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment.结核病治疗停止后贝达喹啉的微异质性耐药
N Engl J Med. 2019 May 30;380(22):2178-2180. doi: 10.1056/NEJMc1815121.
6
Clofazimine Exposure Selects Efflux Pump Mutants and Bedaquiline Resistance.氯法齐明暴露选择外排泵突变体和贝达喹啉耐药性。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02141-18. Print 2019 Mar.
7
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素：一项个体患者数据荟萃分析。
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
8
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.贝达喹啉对南非耐多药结核病患者死亡率的影响：一项回顾性队列研究。
Lancet Respir Med. 2018 Sep;6(9):699-706. doi: 10.1016/S2213-2600(18)30235-2. Epub 2018 Jul 11.
9
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.在未记录有先前使用氯法齐明或贝达喹啉情况的耐多药结核病患者中，与耐药相关的Rv0678变体意外地具有高流行率。
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690. doi: 10.1093/jac/dkw502.
10
A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.一项多实验室、多国研究，以确定用于表型药敏试验的贝达喹啉最低抑菌浓度质量控制范围。
J Clin Microbiol. 2016 Dec;54(12):2956-2962. doi: 10.1128/JCM.01123-16. Epub 2016 Sep 21.